Financials
Financial year 2025
PHARMA-EUROPE from Ottignies-Louvain-la-Neuve, company number BE0645778092, closed financial year 2025 with a result of € 1.1 million after tax. For that financial year PHARMA-EUROPE recorded a gross margin of € 1.9 million and equity of € 2.7 million. Compared with financial year 2024, the result moved from € 1.1 million to € 1.1 million. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 2.7 million
▼ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.1 million
▲ 4% vs 2024
Profit after tax over the fiscal year.
€ 575,704
▼ 45% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.6 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
3.7
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 374,084
▲ 48% vs 2024
€ 101,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 23,765
▲ € 20,166 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.1 million
▲ € 924,422 vs 2024
€ 105,169 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 812,510
▼ 15% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 69,932
▲ 40% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 595,516 | € 881,987 | € 1,856,045 | € 1,930,995 | ▲ 4% |
| Profit after taxes | € 306,453 | € 483,984 | € 1,102,325 | € 1,144,833 | ▲ 4% |
| Equity | € 1,583,139 | € 2,067,123 | € 3,169,448 | € 2,689,281 | ▼ 15% |
| Total debts | € 681,510 | € 1,755,278 | € 1,222,299 | € 2,034,785 | ▲ 66% |
| Cash | € 396,523 | € 555,222 | € 1,040,455 | € 575,704 | ▼ 45% |
| Land & buildings | € 472,165 | € 454,181 | € 735,908 | € 715,335 | ▼ 3% |
| Retained profit | € 1,537,639 | € 2,021,623 | € 3,123,948 | € 2,643,781 | ▼ 15% |
| Dividend | € 0 | € 0 | € 0 | € 1,625,000 | |
| Bank debt | € 306,429 | € 428,331 | € 210,053 | € 1,134,475 | ▲ € 924,422 |
| Balance sheet total | € 2,264,649 | € 3,822,401 | € 4,420,747 | € 4,724,065 | ▲ 7% |
| Employees (FTE) | 2 | 2.7 | 3.6 | 3.7 | ▲ 0.1 |
Key figures of PHARMA-EUROPE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA-EUROPE?
What happened at PHARMA-EUROPE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.1 million (▲ 4% vs 2024). filed late Source: NBB ↗
- New establishment in Mont-Saint-Guibert. KBO
- New establishment in Ottignies-Louvain-la-Neuve. KBO
- Start of the company according to the CBE. KBO
In short
From € 306,453 profit in 2022 to € 1.1 million profit in 2025.
Paid € 1 million in corporate taxes since 2022.
Best year ever: 2025, with € 1.1 million profit.
On average € 521,900 of value added per employee in 2025.
A new publication or filing at PHARMA-EUROPE? We notify you, reason included.
Follow PHARMA-EUROPEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of B&C Groupe comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMA-EUROPEBehind PHARMA-EUROPE is B&C Groupe SRL. The shares are held by B&C Groupe (100%).
Directors
According to the 2025 annual accounts
Director · represented by Bertrand Charlier
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de Namur 12 box 2
1340 Ottignies-Louvain-la-Neuve
Rue des Sablières 45
1435 Mont-Saint-Guibert
Active since 1 January 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0645.778.092
- VAT number
- BE 0645.778.092
- Registered office
- Rue de Namur 12 bus 2, 1340 Ottignies-Louvain-la-Neuve
- Names & denominations
- PHARMA-EUROPE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 January 2016
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren